Study of sacituzumab tirumotecan combination for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of drugs (sacituzumab tirumotecan plus others) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination works better for those who have not had treatment before or whose cancer progressed after one line of therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of esophageal cancer called squamous cell carcinoma that cannot be removed by surgery or has spread to other parts of the body.
- You either have not had any cancer treatment before OR you have tried one previous treatment (chemo or chemo plus immunotherapy) and it stopped working or caused too many side effects.
- You are able to take care of yourself (ECOG score of 0 or 1) and your doctor expects you to live at least 12 more weeks.
- Your blood counts, liver, and kidney function must be within certain safe limits (no transfusions or growth factors within 2 weeks before starting the study).
- You must agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial tests a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, for people with advanced esophageal or stomach cancer that has worsened after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new targeted drug (sacituzumab tirumotecan) for people with advanced thymic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug can shrink tumors and improve outcomes.
This trial tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, for people with extensive-stage small cell lung cancer that has worsened after at least two cycles of standard chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This study tests a combination of two drugs: sacituzumab tirumotecan (a targeted antibody-drug conjugate) plus an immunotherapy. It is for people with advanced head and neck cancer whose disease has gotten worse after prior immunotherapy. The goal is to see if this combination can shrink tumors and slow the cancer's growth.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.